For patients who fail to generate endogenous anti-tumor immunity, T cells in the polyclonal blood pool can be engineered to express either a known tumor-specific T cell receptor or a synthetic MHC-independent CAR (43). The gene discussed is HLA-C; the disease is neoplasm.